Trial Profile
Comparing the Pharmacodynamics of Nasal and Buccal Midazolam Using EEG.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2015
Price :
$35
*
At a glance
- Drugs Midazolam (Primary) ; Midazolam (Primary)
- Indications Epilepsy
- Focus Pharmacodynamics
- Acronyms nMDZ-EEG
- 03 Feb 2015 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
- 16 Nov 2012 Planned End Date changed from 1 Apr 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 16 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.